Tagged with CDMO

Sweden Since going public five years ago, Recipharm, Sweden’s iconic indigenous contract development and manufacturing organization (CDMO), has seen its sales skyrocket by over 30 percent annually. Much of this growth has been driven by an acquisition streak with the company plucking up overseas production assets such as former Roche and…

Sweden Thomas Eldered, CEO of Sweden’s largest CDMO Recipharm, founded the company together with his business partner in 1995. Since becoming a public company in 2014, he highlights how this changed the business model and created a pure CDMO whilst increasingly expanding its global footprint both organically and through acquisitions in…

India Unlike many of his pharma peers, Vivek Sharma worked in operations and finance for two decades before joining the life sciences industry as head of Piramal Pharma Solutions (PPS) in 2011. Already established as one of the world’s leading CDMOs with a presence in North America, Europe, and Asia, Sharma…

Switzerland Unknown to some, Switzerland meanwhile remains both influential and relevant in global pharma circles not just for the obvious core activities of research, discovery and marketing, but also for its prowess in outsourced manufacturing. This might seem rather surprising considering the comparatively high cost of Swiss labour relative to the…

Sweden Simon Björklund, CEO of Bioglan, a Swedish CDMO owned by Reig Jofre, explains the company’s twofold business model of developing and manufacturing products for local and international clients. He highlights the advantages of manufacturing and operating in Sweden, while emphasizing his future vision of developing and out-licensing Bioglan’s own products.…

Puerto Rico In 2015, Avara, a fast-growing global pharma CDMO, acquired Merck’s plant located in Arecibo, Puerto Rico. Idalia Garcia, who has been managing the site for the last six years, explains the capabilities the site offers, the reasons why Avara chose to invest in the facility and its people, and the…

Taiwan Shing-Mou Lee, founder and president of EMO Biomedicine, the leading CDMO provider of cell-based products in Taiwan, discusses the major regulatory and maturation trends in the region and shares his future strategy for expanding the company’s position in the sector.   One of EMO’s missions is to help the government…

Taiwan Wei-Hong Tseng, founder and chairman of PharmaCore Biotech, introduces the specialized CDMO and its unique capacities to produce high value-added products. As a leading service provider in Taiwan, Tseng goes on to explain the company’s future strategy to not only continue its international expansion but also further enhance its innovative…

China Dr Shun Luo, chairman, founder and CEO of Thousand Oaks Biopharmaceuticals, shares the company’s vision to deliver more accessible and affordable biologics to patients globally by lowering the cost of goods manufactured (COGM) per gram of recombinant protein; the paradigm-shifting technology and processes Thousand Oaks Biopharmaceuticals is innovating as an…

France Michel Spagnol, chairman and CEO of Novasep, a robust French CDMO, shares his insights on the key global trends that are shaping today’s CMDO sector – particularly the emerging significance of biopharmaceuticals and gene therapies. Spagnol goes on to elaborate on his strategy to revitalize Novasep’s organizational structure and position…

France Patrick Mahieux, general manager of ABL Europe, a CDMO specialized in the provision of viral vectors, discusses the company’s history within the Institut Mérieux and, the unique and flexible strategy Mahieux leverages to position the CMO as a top player in the market.   We manage ABL Europe as a…

France David Lescuyer, managing director of Skyepharma, a specialized CDMO, reflects on the past three years of the company as it transitioned from a drug delivery platform to a fully-fledged service provider leveraging agile solutions across the value chain. Lescuyer also shares his insights on the service sector and the most…